214 related articles for article (PubMed ID: 24804215)
1. Extracellular matrix proteins expression profiling in chemoresistant variants of the A2780 ovarian cancer cell line.
Januchowski R; Zawierucha P; Ruciński M; Nowicki M; Zabel M
Biomed Res Int; 2014; 2014():365867. PubMed ID: 24804215
[TBL] [Abstract][Full Text] [Related]
2. Microarray-based detection and expression analysis of extracellular matrix proteins in drug‑resistant ovarian cancer cell lines.
Januchowski R; Zawierucha P; Ruciński M; Zabel M
Oncol Rep; 2014 Nov; 32(5):1981-90. PubMed ID: 25199881
[TBL] [Abstract][Full Text] [Related]
3. Gene expression analysis of drug-resistant MCF-7 cells: implications for relation to extracellular matrix proteins.
Işeri OD; Kars MD; Arpaci F; Gündüz U
Cancer Chemother Pharmacol; 2010 Feb; 65(3):447-55. PubMed ID: 19543729
[TBL] [Abstract][Full Text] [Related]
4. Drug transporter expression profiling in chemoresistant variants of the A2780 ovarian cancer cell line.
Januchowski R; Zawierucha P; Ruciński M; Andrzejewska M; Wojtowicz K; Nowicki M; Zabel M
Biomed Pharmacother; 2014 May; 68(4):447-53. PubMed ID: 24814220
[TBL] [Abstract][Full Text] [Related]
5. The Role of Matrix Gla Protein (MGP) Expression in Paclitaxel and Topotecan Resistant Ovarian Cancer Cell Lines.
Sterzyńska K; Klejewski A; Wojtowicz K; Świerczewska M; Andrzejewska M; Rusek D; Sobkowski M; Kędzia W; Brązert J; Nowicki M; Januchowski R
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257426
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10.
Varma RR; Hector SM; Clark K; Greco WR; Hawthorn L; Pendyala L
Oncol Rep; 2005 Oct; 14(4):925-32. PubMed ID: 16142353
[TBL] [Abstract][Full Text] [Related]
7. Microarray-based detection and expression analysis of ABC and SLC transporters in drug-resistant ovarian cancer cell lines.
Januchowski R; Zawierucha P; Andrzejewska M; Ruciński M; Zabel M
Biomed Pharmacother; 2013 Apr; 67(3):240-5. PubMed ID: 23462296
[TBL] [Abstract][Full Text] [Related]
8. The Significance of MicroRNAs Expression in Regulation of Extracellular Matrix and Other Drug Resistant Genes in Drug Resistant Ovarian Cancer Cell Lines.
Kazmierczak D; Jopek K; Sterzynska K; Ginter-Matuszewska B; Nowicki M; Rucinski M; Januchowski R
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32283808
[TBL] [Abstract][Full Text] [Related]
9. Microarray-based detection and expression analysis of new genes associated with drug resistance in ovarian cancer cell lines.
Januchowski R; Sterzyńska K; Zawierucha P; Ruciński M; Świerczewska M; Partyka M; Bednarek-Rajewska K; Brązert M; Nowicki M; Zabel M; Klejewski A
Oncotarget; 2017 Jul; 8(30):49944-49958. PubMed ID: 28611294
[TBL] [Abstract][Full Text] [Related]
10. New and Old Genes Associated with Primary and Established Responses to Cisplatin and Topotecan Treatment in Ovarian Cancer Cell Lines.
Świerczewska M; Klejewski A; Wojtowicz K; Brązert M; Iżycki D; Nowicki M; Zabel M; Januchowski R
Molecules; 2017 Oct; 22(10):. PubMed ID: 29027969
[TBL] [Abstract][Full Text] [Related]
11. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.
Zeller C; Dai W; Steele NL; Siddiq A; Walley AJ; Wilhelm-Benartzi CS; Rizzo S; van der Zee A; Plumb JA; Brown R
Oncogene; 2012 Oct; 31(42):4567-76. PubMed ID: 22249249
[TBL] [Abstract][Full Text] [Related]
12. Mutual Expression of ALDH1A1, LOX, and Collagens in Ovarian Cancer Cell Lines as Combined CSCs- and ECM-Related Models of Drug Resistance Development.
Sterzyńska K; Klejewski A; Wojtowicz K; Świerczewska M; Nowacka M; Kaźmierczak D; Andrzejewska M; Rusek D; Brązert M; Brązert J; Nowicki M; Januchowski R
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30583585
[TBL] [Abstract][Full Text] [Related]
13. MDR gene expression analysis of six drug-resistant ovarian cancer cell lines.
Januchowski R; Wojtowicz K; Sujka-Kordowska P; Andrzejewska M; Zabel M
Biomed Res Int; 2013; 2013():241763. PubMed ID: 23484165
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
15. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
16. Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells.
Xu J; Wu J; Fu C; Teng F; Liu S; Dai C; Shen R; Jia X
J Cell Physiol; 2018 Jun; 233(6):5034-5043. PubMed ID: 29219179
[TBL] [Abstract][Full Text] [Related]
17. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
18. Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer.
Zou J; Yin F; Wang Q; Zhang W; Li L
Int J Clin Exp Pathol; 2015; 8(6):6847-58. PubMed ID: 26261572
[TBL] [Abstract][Full Text] [Related]
19. EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer.
Haslehurst AM; Koti M; Dharsee M; Nuin P; Evans K; Geraci J; Childs T; Chen J; Li J; Weberpals J; Davey S; Squire J; Park PC; Feilotter H
BMC Cancer; 2012 Mar; 12():91. PubMed ID: 22429801
[TBL] [Abstract][Full Text] [Related]
20. Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels.
Stewart JJ; White JT; Yan X; Collins S; Drescher CW; Urban ND; Hood L; Lin B
Mol Cell Proteomics; 2006 Mar; 5(3):433-43. PubMed ID: 16319398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
